Aims: Sarsasapogenin has been reported to improve dementia symptoms somehow, probably through modulating the function of cholinergic system, suppressing neurofibrillary tangles, and inhibiting inflammation. However, the role of sarsasapogenin in response to beta-amyloid (Aβ) remains to be delineated. This study aimed to determine the therapeutic effect of sarsasapogenin-13 (AA13, a sarsasapogenin derivative) on learning and memory impairments in Aβ-injected mice, as well as the role of AA13 in neuroglia-mediated antiinflammation and Aβ clearance.
the brain, which finally causes sporadic AD.
3 With regard to inflammation hypothesis, a chronic neuroinflammatory response to Aβ deposits exacerbates the neurodegenerative pathology. 4 Emerging evidences showed that activated microglia can be divided into "classic" or "alternative" activated populations, as also known as M1 and M2 microglia.
M1 microglia secretes abundant proinflammatory cytokines, which can lead to tissue injury and contribute to pathogenesis, whereas M2 microglia tend to produce antiinflammatory factors and neurotrophins, and promote angiogenesis, tissue remodeling, and repair. 5 Therefore, somehow enhancing the glial ability to eliminate Aβ and shifting glia from M1 to M2 phenotype are extremely interested.
Neuroglia, mainly referring to microglia and astrocytes, play an essential role in maintaining homeostasis and performing defense in the central nervous system (CNS). Previous studies have demonstrated that Aβ plaques are surrounded by abundant reactive glia. 6, 7 Several mechanisms are involved in the initial defense against toxic Aβ accumulation, including enzymatic degradation, receptor-mediated pathway and phagocytosis. Primary astrocytes were reported to bind and ingest Aβ in vitro. 8 Thereinto, scavenger receptors (SRs), macrophage scavenger receptor 1 (MSR1), fatty acid translocase (CD36), and scavenger receptor class B member 1 (SCARB1) closely correlate with Aβ recognition and assimilation. 9, 10 Besides, the high expression of Aβ-degrading proteases, such as neprilysin (NEP), endothelin-converting enzyme (ECE), and insulin-degrading enzyme (IDE), effectively promotes the Aβ removal. 11, 12 Preceding studies have found the deficient microglial elimination of toxic Aβ 13 and high level of proinflammatory factors in AD. 14 The modest activated microglia produce inflammatory cytokines and chemokines and also raise phagocytic efficiency. 15, 16 However, excessive activation of microglia conversely increases Aβ accumulation and injures neurons. The cytokines induced by Aβ in turn reduce the expression of Aβ-degrading enzymes and Aβ-binding receptors, which do harm to the brain function. 17, 18 Taken together, the proper therapeutic method for AD is to alleviate the proinflammatory response and enhance elimination of Aβ. Rhizoma anemarrhenae is isolated from the rhizome of Anemarrhena asphodeloides Bge. The saponins possess ample pharmacological activities, such as antiviral, antiinflammatory, antidiabetic, and antifungal.
Intracerebroventricular (i.c.v.) injection of Aβ
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Early investigation has discovered that timosaponin AIII ameliorates learning and memory deficits by inhibiting the expression of cholinesterase (AChE) and inflammatory cytokines. 24, 25 Recent research showed that the "sarsasapogenin-aglyconed" timosaponins played a role in lowering Aβ 1-42 production and stimulating neurite outgrowth.
26
Sarsasapogenin-AA13 (AA13) was found to inhibit inflammation 27 and stimulate the secretion of neurotrophic factors (data not shown) in our previous study. This study aimed to determine the therapeutic effect of AA13 on learning and memory impairments in Aβ-injected mice, as well as the role of AA13 in neuroglia-mediated antiinflammation and Aβ clearance.
| MATERIALS AND METHODS
| Materials
Dulbecco's modified Eagle's medium and F12 HAMS medium were purchased from Hyclone Laboratories (Logan, UT, USA). Fetal bovine serum (FBS) and GlutaMAX medium were from Gibco BRL (Grand Island, NY, USA). Dimethylsulfoxide (DMSO) and paraformaldehyde (PFA) were from Sigma Aldrich (St Louis, MO, USA). 3-(4,
and trypsin were purchased from Sangon Biotech (Shanghai, China).
EDTA-2Na and glycerinum were from Sinopharm Chemical Reagent
Co., Ltd (Shanghai, China). Bovine serum albumin (BSA) was purchased from Aladdin Industrial Inc (Shanghai, China).
AA13, a derivative of natural compound sarsasapogenin, was synthesized by Lei Ma's laboratory from School of Pharmacy, East China
University of Science and Technology ( Figure 1A ). 28 A 5 mmol/L of stock solution of AA13 was dissolved in DMSO and stored at −80°C.
The stock solution was diluted to the final concentrations before use, making sure that no detectable effect of DMSO was found in the experiments. 
| Animals and drug treatments
| Morris water maze test
The apparatus, a circular tank (150 cm in diameter and 60 cm in height), was filled with water to a depth of 40 cm. The tank was conceptually divided into four quadrants. Black floating granules were tiled on the surface of water, and an escape platform invisible to the mice was 
| Nissl staining
Mice were perfused with 4% paraformaldehyde (PFA), and then brains were cut into 20-μm-thick cerebral sections in a cryostat (Leica CM 1950, Germany). The frozen sections were mounted on gelatincoated slides, dried completely, and rehydrated in distilled water.
Then, the sections were immersed in Nissl staining solution (Beyotime Biotechnology) for 10 minutes and rinsed in distilled water. After dehydrating in graded series of ethanol, the sections were submerged in xylene for 5 minutes, cover-slipped with neutral balsam, and dried naturally.
| Primary cell culture
Primary microglia and astrocytes were isolated from neonatal SpragueDawley (SD) rats and cultured as previously described with some modification. 30, 31 In brief, 8-10 neonatal rats were decapitated after absolute disinfection. Cerebral cortex was separated from the brain and the outside blood vessels and meninges were removed. Then, the cortical tissue was kept in complete medium, minced with ophthalmic scissors, and transferred to a 50-mL centrifugal tube (Corning, NY, USA). Then, the cells were dispersed through gently pipetting repeatedly. After filtration with a 70-μm cell strainer (Biologix Group Ltd, Shandong, China), the cell suspension was then spun down at 200 g for 10 minutes. The cell pellets were resuspended with complete medium, plated in T75 flasks (Corning) at a concentration of 1.5×10 6 cells/mL, and maintained in a humidified atmosphere of 95% air and 5% CO 2 at 37°C. The fresh medium was changed every 3 days. 
| Measurement of cell viability
Cell viability of microglia and astrocytes with different treatments was evaluated by MTT assay. 32 Cells were seeded into 96-well plates in an appropriate density. After various treatments for 24 hours, MTT (0.25 mg/mL) was added to each well. The plates were incubated for 4 hours at 37°C; then, the medium was discarded gently.
The formazan particles were dissolved in DMSO. Finally, the plates were shaken mildly for 5 minutes to get the particles completely dissolved and the absorbance was read at 490 nm using a Synergy™ 2 multimode microplate readers (Bio Tek, Winooski, VT, USA).
| Immunofluorescence staining
The cells seeded on the inserted coverslips (Nest Biotechnology, Wuxi, Jiangsu, China) were treated with AA13 (10 μmol/L) for 24 hours and fixed with 4% PFA for 15 minutes at room temperature (RT). Then, the cells on coverslips were rinsed with PBS to remove cellular debris, blocked with blocking buffer (5% BSA and 0.3% Triton-× 100 in PBS) for 2 hours, and incubated with the rabbit anti-Iba1 polyclonal antibody (Proteintech, Wuhan, China) overnight in a humidified chamber at 4°C. After washing three times in PBS, the cells were incubated with an Alexa Fluor 488-conjugated secondary anti-rabbit antibody (Invitrogen, MO, USA) for 2 hours at RT in dark. The fluorescent images were captured using a Nikon fluorescent microscope (Nikon, Tokyo, Japan).
| Western blot
The various treated cells were harvested and lysed in cell lysis buffer 
| Clearance of Aβ 1-42
The cells were plated into 24-well plates overnight until the cells reached 80% confluence. Then, the medium was replaced by serum- 
| In vitro phagocytosis assay
The phagocytic ability of primary microglia was determined by the 
| Statistical analysis
Results were presented as mean±standard error of the mean (SEM) of three independent experiments. One-way analysis of variance 
| RESULTS
| AA13 treatment ameliorates learning and memory impairment in Aβ 1-42 -injected mice
The learning and memory function was evaluated by the Morris water maze test. As for escape latency, two-way ANOVA indicated significant differences among different groups in the training trial [F group (3168)=3.551, P=.016; Figure 1D ]. Furthermore, the mean escape la- Figure 1F ).
And Figure 1C shows 
| AA13 alleviates Aβ 1-42 -induced cytotoxicity in primary neuroglia
To evaluate the effect of AA13 on ameliorating Aβ (Figure 2A and B). AA13 apparently alleviated the Aβ 1-42 -induced cytotoxicity (up to 16.3% in astrocytes and 23.0% in microglia).
The morphological alterations elicited by AA13 in Aβ 1-42 -challenged cells were documented. As shown in Figure 2C , the Aβ 1-42 -treated astrocytes showed obvious shrinkage, widened intercellular gaps, and increased ramified cells. In normal microglia, many long branches extended from cellular soma. Most of the Aβ 1-42 -treated microglia displayed ameboid shape with enlarged soma and thickened processes ( Figure 2D ). However, the abovementioned morphological changes in astrocytes and microglia were partially reversed after AA13 treatment.
These results demonstrated that AA13 could protect neuroglia against Aβ 1-42 -induced cellular damage.
| AA13 promotes differentiation of glia from proinflammatory M1 to antiinflammatory M2 phenotype
As shown in results, Aβ alone did not affect Arg-1 and Ym 1/2 expressions obviously. However, AA13 pretreatment markedly increased Arg-1 and Ym 1/2 protein expression in astrocytes ( Figure 3A and B) and microglia ( Figure 3E and F) . Besides, Aβ significantly increased the expression of TNF-α and iNOS, which was then attenuated by incubation of AA13 in glia (Figure 3C , D, G, and H). The results indicated that AA13 exposure reversed the upregulation of M1 markers and increased the expression of M2 markers in Aβ-treated glia. 
| AA13 increases Aβ
| AA13 promotes microglial activation and reinforces phagocytic efficiency
The activation of microglia results in transformation of cellular morphology and function. Figure 5F ). 1 μmol/L AA13 treatment had no effect.
These results illustrated that AA13 could activate microglia and promote phagocytosis, which may be partially correlated with CD36.
| AA13 treatment impacts on the expression of Aβ-degrading enzymes
NEP, ECE, and IDE are potent Aβ-degrading enzymes in the brain; their expression greatly influences Aβ clearance. We performed western blot to determine the effect of AA13 on the expression of Aβ-degrading enzymes in cultured primary glia. As demonstrated in Figure 6A and B, the expression of IDE and NEP notably increased after AA13 treatment in a dose-dependent manner in astrocytes.
Inversely, AA13 exerted a negative effect on ECE; that is, 10 μmol/L AA13 decreased the expression of ECE ( Figure 6C ). Interestingly, microglial ECE protein was markedly augmented by AA13 ( Figure 6F ), but the expression of IDE and NEP was reduced by high-dose AA13
( Figure 6D and E) . These results suggested that AA13 could regulate the expression of Aβ-degrading enzymes in astrocytes and microglia to promote elimination of Aβ protein. In the previous study, we have found that AA13 markedly ameliorated the cognitive deficit induced by scopolamine, 28 mainly through upregulating the expression of BDNF and PSD95 in cortex (data not shown), which might prompt the neuroprotective potential of AA13.
| DISCUSSION
Neuroinflammation from aberrantly activated glia is an important mechanism that contributes to AD progression. To learn more about the potential mechanisms of AA13 on curing neurodegenerative diseases, in this study, we used Aβ 47 Another study in our laboratory indicated that in APP/PS1 mice, NEP levels showed a significant decrease with age, while ECE protein significantly increased in the cerebral cortex and hippocampus. 48 Similarly, Liu et al. found that astrocytes from AD mice expressed more NEP than the WT group, and NEP protein level gradually rose with time. 49 In the current study, we found that AA13 regulated the Aβ-degrading enzyme expression differently in microglia and astrocytes. AA13 treatment increased IDE and NEP expression, but decreased ECE expression in astrocytes. In contrast, expression of IDE and NEP was reduced in microglia, while the ECE level was significantly enhanced along with the increased drug concentration. These results indicated that AA13 treatment played an important role in Aβ degradation through regulating Aβ-degrading enzyme expression. Interestingly, it seems that microglia tend to remove Aβ through phagocytosis, while astrocytes prefer to enzymatic degradation.
| CONCLUSION
Our finding illustrated that oral administration of AA13 attenuated the cognitive impairment in Aβ-injected mice; also, AA13 alleviated Aβ-induced cytotoxicity in primary cultured glia. The mechanical studies found that AA13 promoted differentiation of neuroglial cells from proinflammatory M1 to antiinflammatory M2 phenotype. Moreover, 
